Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology

27 February 2019

Helsinn Investment Fund Invests €1 Million in Gain Therapeutics

19 February 2019

Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood Advances

14 February 2019

Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care

31 January 2019

Wound Care: new clinical data show Nexodyn® AOS To reduce reinfections and healing time in diabetic foot ulcers

31 January 2019

Ebola: Promising Early-Stage Safety Clinical Trial Results For Potential Treatment Based On Antibodies Isolated In Switzerland

25 January 2019

Gabriel Haering at the Career Chat c/o ETH Zurich

17 January 2019

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

21 December 2018

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®

20 December 2018

Advitech’s new project: APIsTRENDS – a collection of reports

18 December 2018